Mark Hillman
Net sellingHillman Capital Management, Inc. — managed by Mark Hillman; US equity positions disclosed quarterly via SEC 13F
Data as of 2026-06-30 (filed 2026-08-14) · Source: SEC EDGAR
New
Added
Exited
By what price implies: 24 demand a demanding growth rate, 6 modest.
13F × valuation
Valuation posture
Of 16 valued US positions, 5 trade below a conservative value band (as of 2026-09-03):
- IntuitINTU33% · below
- Fiserv IncFISV21% · below
- Adobe IncADBE18% · below
- Accenture Plc IrelandACN9% · below
- Bristol-Myers Squibb CoBMY3% · below
SEC 13F · latest filing
Holdings
- Cvs Health CorpCVSCore 8qValue$5.7MValuation—Holders14Weight4.2%
- Biogen IncBIIBCore 8qValue$5.2MValuation—Holders3Weight3.8%
- Dupont De Nemours IncDDBig newValue$5.1MValuation—Holders3Weight3.7%
- Warner Bros Discovery IncWBDCore 8qValue$5.1MValuation—Holders6Weight3.7%
- Baxter Intl IncBAXCore 8qValue$5.0MValuation—Holders8Weight3.6%
- Value$5.0MValuation—Holders6Weight3.6%
- Value$4.8MValuation—Holders8Weight3.5%
- Value$4.8MValuation—Holders5Weight3.5%
- Value$4.7MValuation—Holders8Weight3.4%
- Value$4.6MValuation—Holders8Weight3.4%
- Value$4.6MValuation—Holders10Weight3.4%
- Value$4.6MValuation—Holders7Weight3.3%
- Value$4.2MValuation—Holders11Weight3.0%
- Value$4.0MValuation—Holders5Weight2.9%
- Value$3.8MValuationBelow valueHolders9Weight2.8%
- Value$3.8MValuation—Holders43Weight2.8%
- Value$3.6MValuation—Holders3Weight2.6%
- Value$3.5MValuationBelow valueHolders13Weight2.6%
- Ishares TrEFAAdding 5qValue$3.3MValuation—Holders4Weight2.4%
- Value$3.2MValuation—Holders7Weight2.3%
- Value$2.7MValuation—Holders28Weight1.9%
- Value$2.6MValuationBelow valueHolders9Weight1.9%
- Value$2.6MValuation—Holders4Weight1.8%
- Value$2.5MValuation—Holders9Weight1.8%
- Value$2.5MValuation—Holders8Weight1.8%
Showing top 25 of 54 positions
About this investor
About this investor
Portfolio overview
Hillman Capital Management, Inc.'s most recent 13F filing, for the quarter ended 2026-06-30, reports 54 positions worth $138.2M. The top 5 holdings represent 19% of that value, a broadly diversified portfolio.
The single largest position is Cvs Health Corp at 4.2% of the portfolio, followed by Biogen Inc at 3.8% and Dupont De Nemours Inc at 3.7%.
Against the prior quarter, Mark Hillman opened 3 new positions, exited 5, added to 14, and trimmed 35. The largest new buy was Dupont De Nemours Inc. The most notable sale was the full exit from Dupont De Nemours Inc.
Across all 8 quarters on file, Cvs Health Corp has appeared in every filing, as has Biogen Inc. Cvs Health Corp currently ranks first by value.
A 13F is filed roughly 45 days after quarter-end and covers only long positions in US-listed equities, so it is a lagging and partial view of the portfolio. Source: SEC EDGAR.
Mark Hillman has no positions in the strike zone right now. Browse the whole market by value band
Sources· SEC EDGAR 13F as of 2026-06-30 · filed 2026-08-14
Stay Updated
New-quarter 13F moves and valuation updates, to your inbox.